A meta-analysis of convalescent plasma in the treatment of patients with severe coronavirus disease 2019

YANG Cheng; FENG Chunlu; LIU Min; TUO Lin; GENG Xiaoxia; YANG Xingxiang

doi:10.7619/jcmp.20220999

Journal of Clinical Medicine in Practice > 2022 > 26(11): 6-11. > DOI: 10.7619/jcmp.20220999

YANG Cheng, FENG Chunlu, LIU Min, TUO Lin, GENG Xiaoxia, YANG Xingxiang. A meta-analysis of convalescent plasma in the treatment of patients with severe coronavirus disease 2019[J]. Journal of Clinical Medicine in Practice, 2022, 26(11): 6-11. DOI: 10.7619/jcmp.20220999

Citation:

PDF (2744 KB)

A meta-analysis of convalescent plasma in the treatment of patients with severe coronavirus disease 2019

YANG Cheng^{1, 2},
FENG Chunlu^{1, 2},
LIU Min^{2, 3},
TUO Lin²,
GENG Xiaoxia^{1, 2},
YANG Xingxiang^{1, 2, 3, ,}

1.
School of Medicine of University of Electronic Science and Technology of China, Chengdu, Sichuan, 610054
2.
Department of Infection, Sichuan Provincial People′s Hospital, Chengdu, Sichuan, 610072
3.
Chengdu Medical College, Chengdu, Sichuan, 610500

More Information

Received Date: March 28, 2022
Available Online: May 16, 2022

Graphical Abstract

Abstract

Abstract

Objective
To evaluate the effectiveness and safety of convalescent plasma in treatment of patients with severe coronavirus disease 2019(COVID-19) by meta-analysis.
Methods
Databases such as EMBASE, PubMed, Web of Science, Cochrane Library, China National Knowledge Infrastructure(CNKI) and Chinese Biomedical Literature Database were searched to collect randomized controlled trials (RCTs) about convalescent plasma therapy for severe COVID-19, and the search deadline was December 1, 2021. The efficacy evaluation indexes included 28 d or 30 d mortality and discharge rate, and the safety evaluation index was the incidence of adverse events. A meta-analysis was performed by using RevMan 5.3 software.
Results
A total of 9 RCTs including 3 461 patients were enrolled in this meta-analysis, and the results showed that there were no significant differences in the 28 d or 30 d all-cause mortality (RR=0.94, 95%CI, 0.84 to 1.05, P=0.27), 28 d or 30 d discharge rate (RR=1.06, 95%CI, 0.95 to 1.19, P=0.28) and incidence of adverse events (RR=1.16, 95%CI, 0.71 to 1.88, P=0.55)between routine regimen and convalescent plasma.
Conclusion
meta-analysis of this study suggests that the convalescent plasma is safe in the treatment of patients with severe COVID-19, but it has no significant improvement in short-term mortality and discharge rate.
- convalescent plasma,
- coronavirus disease 2019,
- systematic analysis,
- all-cause mortality,
- databases,
- safety,
- effectiveness

FullText(HTML)

References (22)

References

[1]	LI C, REN L Z. Recent progress on the diagnosis of 2019 novel coronavirus[J]. Transbound Emerg Dis, 2020, 67(4): 1485-1491. doi: 10.1111/tbed.13620
[2]	BURNOUF T, SEGHATCHIAN J. Ebola virus convalescent blood products: where we are now and where we may need to go[J]. Transfus Apher Sci, 2014, 51(2): 120-125. doi: 10.1016/j.transci.2014.10.003
[3]	RAJAM G, SAMPSON J, CARLONE G M, et al. An augmented passive immune therapy to treat fulminant bacterial infections[J]. Recent Pat Antiinfect Drug Discov, 2010, 5(2): 157-167. doi: 10.2174/157489110791233496
[4]	DEVASENAPATHY N, YE Z K, LOEB M, et al. Efficacy and safety of convalescent plasma for severe COVID-19 based on evidence in other severe respiratory viral infections: a systematic review and meta-analysis[J]. CMAJ, 2020, 192(27): E745-E755. doi: 10.1503/cmaj.200642
[5]	ROJAS M, RODRÍGUEZ Y, MONSALVED M, et al. Convalescent plasma in Covid-19: possible mechanisms of action[J]. Autoimmun Rev, 2020, 19(7): 102554. doi: 10.1016/j.autrev.2020.102554
[6]	朱鑫方, 王苑, 杜丹心, 等. 康复者恢复期血浆在病毒性疾病治疗中的研究进展[J]. 临床输血与检验, 2020, 22(4): 337-342. doi: 10.3969/j.issn.1671-2587.2020.04.001
[7]	中华人民共和国卫生健康委员会. 新型冠状病毒肺炎诊疗方案(试行第八版修正版)[EB/OL]. (2021-04-05)[2022-03-25]. http://www.nhc.gov.cn/yzygj/s7653p/202104/7de0b3837c8b4606a0594aeb0105232b/files/f192ac6e5567469db4f0a8691ca18907.pdf.
[8]	SIMONOVICHV A, BURGOS PRATXL D, SCIBONA P, et al. A randomized trial of convalescent plasma in covid-19 severe pneumonia[J]. N Engl J Med, 2021, 384(7): 619-629. doi: 10.1056/NEJMoa2031304
[9]	LI L, ZHANG W, HU Y, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: arandomized clinical trial[J]. JAMA, 2020, 324(5): 460-470. doi: 10.1001/jama.2020.10044
[10]	AGARWAL A, MUKHERJEE A, KUMAR G, et al. Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase Ⅱ multicentre randomised controlled trial (PLACID Trial)[J]. BMJ, 2020, 371: m3939.
[11]	WRITING COMMITTEEFORTHE REMAP-CAP INVESTIGATORS, ESTCOURTL J, TURGEONA F, et al. Effect of convalescent plasma on organ support-free days in critically ill patients with COVID-19: arandomized clinical trial[J]. JAMA, 2021, 326(17): 1690-1702.
[12]	ALQAHTANI M, ABDULRAHMAN A, ALMADANI A, et al. Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease[J]. Sci Rep, 2021, 11(1): 9927. doi: 10.1038/s41598-021-89444-5
[13]	BAR K J, SHAW P A, CHOI G H, et al. A randomized controlled study of convalescent plasma for individuals hospitalized with COVID-19 pneumonia[J]. J Clin Invest, 2021, 131(24): e155114. doi: 10.1172/JCI155114
[14]	SEKINE L, ARNS B, FABROB R, et al. Convalescent plasma for COVID-19 in hospitalised patients: an open-label, randomised clinical trial[J]. Eur Respir J, 2022, 59(2): 2101471. doi: 10.1183/13993003.01471-2021
[15]	RAY Y, PAULS R, BANDOPADHYAY P, et al. A phase 2 single center open label randomised control trial for convalescent plasma therapy in patients with severe COVID-19[J]. Nat Commun, 2022, 13(1): 383. doi: 10.1038/s41467-022-28064-7
[16]	O'DONNELLM R, GRINSZTEJN B, CUMMINGSM J, et al. A randomized double-blind controlled trial of convalescent plasma in adults with severe COVID-19[J]. J Clin Invest, 2021, 131(13): e150646. doi: 10.1172/JCI150646
[17]	GROUP R C. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial[J]. Lancet, 2021, 397(10289): 2049-2059.
[18]	JOYNER M J, BRUNO K A, KLASSEN S A, et al. Safety update: COVID-19 convalescent plasma in 20, 000 hospitalized patients[J]. Mayo Clin Proc, 2020, 95(9): 1888-1897. doi: 10.1016/j.mayocp.2020.06.028
[19]	LIBSTER R, MARC G P, WAPPNER D, et al. Early high-titer plasma therapy to prevent severe covid-19 in older adults[J]. N Engl J Med, 2021, 384(7): 610-618. doi: 10.1056/NEJMoa2033700
[20]	SALAZAR E, CHRISTENSENP A, GRAVISSE A, et al. Treatment of coronavirus disease 2019 patients with convalescent plasma reveals a signal of significantly decreased mortality[J]. Am J Pathol, 2020, 190(11): 2290-2303. doi: 10.1016/j.ajpath.2020.08.001
[21]	JOYNERM J, SENEFELDJ W, KLASSENS A, et al. Effect of convalescent plasma on mortality among hospitalized patients with COVID-19: initial three-month experience[J]. medRxiv, 2020, DOI: 10.1101/2020.08.12.20169359.
[22]	DUAN K, LIU B D, LI C S, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients[J]. Proc Natl Acad Sci USA, 2020, 117(17): 9490-9496. doi: 10.1073/pnas.2004168117

[1]	XU Yan, ZHU Chunyun. Monitoring and protection of peripheral blood cell count for nursing staffs in ward after iodine-125 implantation[J]. Journal of Clinical Medicine in Practice, 2023, 27(13): 123-126. DOI: 10.7619/jcmp.20231229
[2]	ZHOU Xiaohua, YIN Guoyong, YU Tingting, WANG Chengyue, SHI Lei, WEI Jincui. Study on the radiation of C-arm X-ray machine to the non-surgical sites of patients undergoing orthopedic surgery[J]. Journal of Clinical Medicine in Practice, 2022, 26(24): 121-124, 148. DOI: 10.7619/jcmp.20222952
[3]	MIU Yihong, DING Xiaoping, WANG Yanhong. Application of comfort care in protective restraint of female patients with mental disorders[J]. Journal of Clinical Medicine in Practice, 2019, 23(16): 111-113. DOI: 10.7619/jcmp.201916030
[4]	REN Xiaomin, CHEN Rong, XU Yinghua. Effect of simple bath protective sleeve in patients with PICC[J]. Journal of Clinical Medicine in Practice, 2018, (8): 73-75. DOI: 10.7619/jcmp.201808022
[5]	CHEN Hao. Effect of comprehensive protective nursing measures in prevention of lower extremity deep venous thrombosis in perioperation[J]. Journal of Clinical Medicine in Practice, 2017, (8): 156-158. DOI: 10.7619/jcmp.201708046
[6]	ZHOU Zhengqing, SHEN Hua, CHEN Yijing. Electroacupuncture in neiguan and dexmedetomidine for hyperglycemia patients with coronary heart disease in protection of myocardial injury during perioperative period[J]. Journal of Clinical Medicine in Practice, 2016, (24): 55-59. DOI: 10.7619/jcmp.201624016
[7]	ZHANG Guoqiang. Effects of Aidi injection and liver protection decoction combined TACE for moderate or advanced primary liver cancer[J]. Journal of Clinical Medicine in Practice, 2015, (Z1): 75-77.
[8]	WEN Yuqin, HE Li, ZHANG Ming. The exploration of limb skin protection method by noninvasive blood pressure measurement in perioperative period[J]. Journal of Clinical Medicine in Practice, 2014, (10): 99-100,103. DOI: 10.7619/jcmp.201410035
[9]	ZHANG Xiu, JIANG Tianjun, WU Dan, LIU Liying, YUAN Hong, TAN Wenhui, Chen Qian, ZHANG Yumin, MA Yafei. Management of occupational protection for AIDS nursing personnel[J]. Journal of Clinical Medicine in Practice, 2012, (20): 98-100.
[10]	LI Xian-hong. Self-protection of nurses working at the liver transplantation center[J]. Journal of Clinical Medicine in Practice, 2005, (4): 6-7. DOI: 10.3969/j.issn.1672-2353.2005.04.004

Cited By

Cited by

Periodical cited type(4)

1.	周炜，蒋俊杰，夏一淼，王利媛，王法财. 替雷利珠单抗药物利用评价标准的建立与应用. 实用药物与临床. 2024(01): 40-45 .
2.	郭小琦，张璞，李小军，余明，王博. 口服醋酸泼尼松联合局部注射曲安奈德对食管早癌ESD术后食管狭窄及肺部感染的预防疗效分析. 中华肺部疾病杂志(电子版). 2024(02): 288-291 .
3.	谢杏梅，高悦. 替雷利珠单抗治疗晚期非小细胞肺癌致免疫相关性胰腺炎1例. 中南药学. 2024(08): 2255-2257 .
4.	赵军华，周志杰，李景萍. 肾病综合征患者应用免疫抑制剂联合激素治疗后并发重症肺炎的相关因素分析. 中国实用医刊. 2024(22): 56-58 .

Other cited types(0)

Get Citation

PDF

XML

Article views (204) PDF downloads (19) Cited by(4)

Turn off MathJax

Article Contents

Abstract

References

A meta-analysis of convalescent plasma in the treatment of patients with severe coronavirus disease 2019